Vis enkel innførsel

dc.contributor.authorBerger, Hester Rijkje
dc.contributor.authorNyman, Axel Karl Gottfrid
dc.contributor.authorMorken, Tora Sund
dc.contributor.authorWiderøe, Marius
dc.date.accessioned2020-02-18T06:21:27Z
dc.date.available2020-02-18T06:21:27Z
dc.date.created2020-01-16T12:41:51Z
dc.date.issued2019
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11250/2642100
dc.description.abstractMelatonin has potential neuroprotective capabilities after neonatal hypoxia-ischemia (HI), but long-term effects have not been investigated. We hypothesized that melatonin treatment directly after HI could protect against early and delayed brain injury. Unilateral HI brain injury was induced in postnatal day 7 rats. An intraperitoneal injection of either melatonin or vehicle was given at 0, 6 and 25 hours after hypoxia. In-vivo MRI was performed 1, 7, 20 and 43 days after HI, followed by histological analysis. Forelimb asymmetry and memory were assessed at 12–15 and at 36–43 days after HI. More melatonin treated than vehicle treated animals (54.5% vs 15.8%) developed a mild injury characterized by diffusion tensor values, brain volumes, histological scores and behavioral parameters closer to sham. However, on average, melatonin treatment resulted only in a tendency towards milder injury on T2-weighted MRI and apparent diffusion coefficient maps day 1 after HI, and not improved long-term outcome. These results indicate that the melatonin treatment regimen of 3 injections of 10 mg/kg within the first 25 hours only gave a transient and subtle neuroprotective effect, and may not have been sufficient to mitigate long-term brain injury development following HI.nb_NO
dc.language.isoengnb_NO
dc.publisherPublic Library of Sciencenb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleTransient effect of melatonin treatment after neonatal hypoxic-ischemic brain injury in ratsnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.volume14nb_NO
dc.source.journalPLOS ONEnb_NO
dc.source.issue12nb_NO
dc.identifier.doi10.1371/journal.pone.0225788
dc.identifier.cristin1774752
dc.description.localcode© 2019 Berger et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.nb_NO
cristin.unitcode1920,1,0,0
cristin.unitcode194,65,15,0
cristin.unitcode1920,16,0,0
cristin.unitcode194,65,25,0
cristin.unitcode1920,11,0,0
cristin.unitcode194,65,30,0
cristin.unitnameBarne- og ungdomsklinikken
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameNevroklinikken
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameKlinikk for ØNH, kjeve- og øyesykdommer
cristin.unitnameInstitutt for nevromedisin og bevegelsesvitenskap
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal